The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: Potential for a role in cancer chemotherapy

FASEB Journal

Volumn 13, Issue 13, 1999, Pages 1724-1732

  Loo, Tip W ^b   Clarke, David M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

Endoplasmic reticulum; Multidrug transporter; Proteasome inhibitor; Protein folding

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DISULFIDE; GLYCOPROTEIN P; LACTACYSTIN; PROTEASOME INHIBITOR; TRYPSIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIOSYNTHESIS; CANCER CHEMOTHERAPY; CELL SURFACE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CROSS LINKING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN PROCESSING;

EID: 0032862993     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fasebj.13.13.1724     Document Type: Article

References (49)

1. Lehnert, M. (1996) Clinical multidrug resistance in cancer: a multifactorial problem. Eur. J. Cancer 6, 912-920
2. Juliano, R. L., and Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152-162
3. Riordan, J. R., and Ling, V. (1985) Genetic and biochemical characterization of multidrug resistance. Pharmacol. Ther. 28, 51-75
4. Biedler, J. L., and Riehm, H. (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1174-1184
5. Shen, D. W., Cardarelli, C., Hwang, J., Cornwell, M., Richert, N., Ishii, S., Pastan, I., and Gottesman, M. M. (1986) Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J. Biol. Chem. 261, 7762-7770
6. Chan, H. S., Grogan, T. M., DeBoer, G., Haddad, G., Gallie, B. L., and Ling, V. (1996) Diagnosis and reversal of multidrug resistance in paediatric cancers. Eur. J. Cancer 6, 1051-1061
7. Fisher, G. A., Lum, B. L., Hausdorff, J., and Sikic, B. I. (1996) Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer 6, 1082-1088
8. Goldstein, L. J. (1996) MDR1 gene expression in solid tumours. Eur. J. Cancer 6, 1039-1050
9. Lee, C. G., Gottesman, M. M., Cardarelli, C. O., Ramachandra, M., Jeang, K. T., Ambudkar, S. V., Pastan, I., and Dey, S. (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37, 3594-3601
10. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M, and Wilkinson, G. R. (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101, 289-294
11. Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P., et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502
12. Schuetz, E. G., Schinkel, A. H., Relling, M. V., and Schuetz, J. D. (1996) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA 93, 4001-4005
13. Charuk, J. H., Grey, A. A., and Reithmeier, R. A. (1998) Identification of the synthetic surfactant nonylphenol ethoxylate: a P-glycoprotein substrate in human urine. Am. J. Physiol. 274, F1127-F1139
14. Higgins, C. F. (1992) ABC transporters: from microorganisms to man. Annu. Rev. Cell. Biol. 8, 67-113
15. Chen, C. J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., and Robinson, I. B. (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47, 381-389
16. Loo, T. W., and Clarke, D. M. (1995) Membrane topology of a cysteine-less mutant of human P-glycoprotein. J. Biol. Chem. 270, 843-848
17. Kast, C., Canfield, V., Levenson, R., and Gros, P. (1996) Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence. J. Biol. Chem. 271, 9240-9248
18. Loo, T. W., and Clarke, D. M. (1994) Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. J. Biol. Chem. 269, 7243-7248
19. Loo, T. W., and Clarke, D. M. (1997) Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J. Biol. Chem. 272, 709-712
20. Loo, T. W., and Clarke, D. M. (1998) Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J. Biol. Chem. 273, 14671-14674
21. Loo, T. W., and Clarke, D. M. (1994) Prolonged association of temperature-sensitive mutants of human P-glycoprotein with calnexin during biogenesis. J. Biol. Chem. 269, 28683-28689
22. Loo, T. W., and Clarke, D. M. (1995) P-glycoprotein. Associations between domains and between domains and molecular chaperones. J Biol. Chem. 270, 21839-21844
23. Loo, T. W., and Clarke, D. M. (1998) Quality control by proteases in the endoplasmic reticulum. Removal of a protease-sensitive site enhances expression of human P-glycoprotein. J. Biol. Chem. 273, 32373-32376
24. - channel is functional when retained in endoplasmic reticulum of mammalian cells. J. Biol. Chem. 270, 12347-12350
25. Loo, T. W., and Clarke, D. M. (1993) Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. J. Biol. Chem. 268, 3143-3149
26. Loo, T. W., and Clarke, D. M. (1995) Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities. J. Biol. Chem. 270, 21449-21452
27. Loo, T. W., and Clarke, D. M. (1996) Inhibition of oxidative cross-linking between engineered cysteine residues at positions 332 in predicted transmembrane segments (TM) 6 and 975 in predicted TM12 of human P-glycoprotein by drug substrates. J. Biol. Chem. 271, 27482-27487
28. Loo, T. W., and Clarke, D. M. (1997) Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12. J. Biol. Chem. 272, 20986-20989
29. Gottesman, M. M., and Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385-427
30. Ambudkar, S. V., Cardarelli, C. O., Pashinsky, I., and Stein, W. D. (1997) Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. J. Biol. Chem. 272, 21160-21166
31. Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., and Riordan, J. R. (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83, 129-135
32. Liu, R., and Sharom, F. J. (1996) Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry 35, 11865-11873
33. Sonveaux, N., Shapiro, A. B., Goormaghtigh, E., Ling, V., and Ruysschaert, J. M. (1996) Secondary and tertiary structure changes of reconstituted P-glycoprotein. A Fourier transform attenuated total reflection infrared spectroscopy analysis. J. Biol. Chem. 271, 24617-24624
34. Urbatsch, I. L., Sankaran, B., Weber, J., and Senior, A. E. (1995) P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J. Biol. Chem. 270, 19383-19390
35. Schinkel, A. H., Kemp, S., Dolle, M., Rudenko, G., and Wagenaar, E. (1993) N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J. Biol. Chem. 268, 7474-7481
36. Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J. L., et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA [published erratum appears in Science 1989, Sept. 29; Vol. 245: 1437]. Science 245, 1066-1073
37. Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O'Riordan, C. R., and Smith. A. E. (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63, 827-834
38. Zhang, F., Kartner, N., and Lukacs, G. L. (1998) Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR. Nat. Struct. Biol. 5, 180-183
39. Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., and Welsh, M. J. (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature (London). 358, 761-764
40. Sato, S., Ward, C. L., Krouse, M. E., Wine, J. J., and Kopito, R. R. (1996) Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. 271, 635-638
41. Brown, C. R., Hong-Brown, L. Q., Biwersi, J., Verkman, A. S., and Welch, W. J. (1996) Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1, 117-125
42. Lukacs, G. L., Mohamed, A., Kartner, N., Chang, X. B., Riordan, J. R., and Grinstein, S. (1994) Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J. 13, 6076-6086
43. Loayza, D., Tam, A., Schmidt, W. K., and Michaelis, S. (1998) Ste6p mutants defective in exit from the endoplasmic reticulum (ER) reveal aspects of an ER quality control pathway in Saccharomyces cerevisiae. Mol. Biol. Cell 9, 2767-2784
44. Ward, C. L., Omura, S., and Kopito, R. R. (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83, 121-127
45. Sato, S., Ward, C. L., and Kopito, R. R. (1998) Cotranslational ubiquitination of cystic fibrosis transmembrane conductance regulator in vitro. J. Biol. Chem. 273, 7189-7192
46. Loo, T. W., and Clarke, D. M. (1997) Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate. J. Biol. Chem. 272, 31945-31948
47. Taubes, G. (1996) Misfolding the way to disease [news]. Science 271, 1493-1495
48. Welch, W. J., and Brown, C. R. (1996) Influence of molecular and chemical chaperones on protein folding [published erratum appears in Cell Stress Chaperones 1996, Sept., Vol. 1: 207]. Cell Stress Chaperones 1, 109-115
49. Thomas, P. J., Qu, B. H., and Pedersen, P. L. (1995) Defective protein folding as a basis of human disease. Trends Biochem. Sci. 20, 456-459